ECSP12011916A - DERIVATIVES OF PIRIDINO-PIRIDINONAS, - Google Patents
DERIVATIVES OF PIRIDINO-PIRIDINONAS,Info
- Publication number
- ECSP12011916A ECSP12011916A ECSP12011916A ECSP12011916A EC SP12011916 A ECSP12011916 A EC SP12011916A EC SP12011916 A ECSP12011916 A EC SP12011916A EC SP12011916 A ECSP12011916 A EC SP12011916A
- Authority
- EC
- Ecuador
- Prior art keywords
- group
- cycle
- alkyl group
- atom
- links
- Prior art date
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108700014844 flt3 ligand Proteins 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- HILFHSXPUWSKCY-UHFFFAOYSA-N pyridine;1h-pyridin-2-one Chemical class C1=CC=NC=C1.O=C1C=CC=CN1 HILFHSXPUWSKCY-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La invención se refiere (i) a derivados de piridino-piridinonas que responden a la fórmula (I) : en la que R1 representa un átomo de hidrógeno o un grupo alquilo(C1-C4) ; R2 representa un grupo -(CH2)n'-B donde n'=0, 1, 2, 3 o 4 y B representa un grupo cicloalquilo(C3-C5), un grupo alquilo(C1-C4) o un grupo alcoxi(C1-C4) ; Y, Z, V y W representan, independientemente entre sí un grupo -CH-, un átomo de carbono, un heteroátomo o ausencia de átomo, entendiéndose que el ciclo, en el que están comprendidos V, W, Y y Z es un ciclo que comprende 5 o 6 eslabones, entendiéndose que las líneas discontinuas en dicho ciclo indican que el ciclo resultante es un ciclo aromático y entendiéndose que dicho ciclo comprende 0, 1 ó 2 heteroátomos ; R3 y R4 representan, independientemente entre sí, grupos idénticos o diferentes, elegidos entre un átomo de hidrógeno ; y un grupo alquilo(C1-C4) lineal o forman junto con el carbono al que están unidos un grupo cicloalquilo(C3-C5) ; m es un número entero igual a 1, 2, 3 ó 4 ; R5 representa un átomo de hidrógeno o un grupo alquilo(C1-C4) ; R6 representa un grupo -(CH2)n-L en el que n= 0, 1, 2 ó 3, y L es un grupo seleccionado entre arilos de 6 átomos de carbono, heteroarilos de 5 ó 6 eslabones, heterociclos saturados que comprenden 5, 6 ó 7 eslabones o forman junto con el átomo de nitrógeno al que están unidos un grupo heterociclo, (ii) a su preparación y (iii) a su aplicación en terapéutica como inhibidores de la actividad quinasa de los receptores de los ligandos PDGFs y/o de los receptores del ligando FLT3.The invention relates (i) to pyridine-pyridinone derivatives that respond to formula (I): wherein R1 represents a hydrogen atom or a (C1-C4) alkyl group; R2 represents a group - (CH2) n'-B where n '= 0, 1, 2, 3 or 4 and B represents a cycloalkyl (C3-C5) group, a (C1-C4) alkyl group or an alkoxy group ( C1-C4); Y, Z, V and W represent, independently of each other a group -CH-, a carbon atom, a heteroatom or absence of an atom, it being understood that the cycle, in which V, W, Y and Z are comprised is a cycle comprising 5 or 6 links, it being understood that the dashed lines in said cycle indicate that the resulting cycle is an aromatic cycle and it being understood that said cycle comprises 0, 1 or 2 heteroatoms; R3 and R4 represent, independently of each other, identical or different groups, chosen from a hydrogen atom; and a linear (C1-C4) alkyl group or together with the carbon to which a cycloalkyl (C3-C5) group is attached; m is an integer equal to 1, 2, 3 or 4; R5 represents a hydrogen atom or a (C1-C4) alkyl group; R6 represents a group - (CH2) nL in which n = 0, 1, 2 or 3, and L is a group selected from aryls of 6 carbon atoms, heteroaryls of 5 or 6 links, saturated heterocycles comprising 5, 6 or 7 links or form together with the nitrogen atom to which a heterocycle group is attached, (ii) to its preparation and (iii) to its application in therapeutics as inhibitors of the kinase activity of PDGFs ligand receptors and / or of FLT3 ligand receptors.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0905602A FR2952934B1 (en) | 2009-11-23 | 2009-11-23 | PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12011916A true ECSP12011916A (en) | 2012-07-31 |
Family
ID=42133583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12011916 ECSP12011916A (en) | 2009-11-23 | 2012-05-21 | DERIVATIVES OF PIRIDINO-PIRIDINONAS, |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8623893B2 (en) |
| EP (1) | EP2504338B1 (en) |
| JP (1) | JP2013511501A (en) |
| KR (1) | KR20120099732A (en) |
| CN (1) | CN102762558A (en) |
| AR (1) | AR079077A1 (en) |
| AU (1) | AU2010320692A1 (en) |
| BR (1) | BR112012012403A2 (en) |
| CA (1) | CA2781935A1 (en) |
| CL (1) | CL2012001322A1 (en) |
| CO (1) | CO6481011A2 (en) |
| CR (1) | CR20120261A (en) |
| DO (1) | DOP2012000136A (en) |
| EA (1) | EA201290383A1 (en) |
| EC (1) | ECSP12011916A (en) |
| FR (1) | FR2952934B1 (en) |
| GT (1) | GT201200154A (en) |
| IL (1) | IL219888A0 (en) |
| MA (1) | MA33819B1 (en) |
| MX (1) | MX2012005988A (en) |
| NI (1) | NI201200095A (en) |
| NZ (1) | NZ600108A (en) |
| PE (1) | PE20121338A1 (en) |
| PH (1) | PH12012501004A1 (en) |
| TN (1) | TN2012000229A1 (en) |
| TW (1) | TWI476197B (en) |
| UY (1) | UY33049A (en) |
| WO (1) | WO2011061458A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| EP2524915A1 (en) * | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| HUE035712T2 (en) * | 2012-07-17 | 2018-05-28 | Sanofi Sa | Use of vegfr-3 inhibitors for treating hepatocellular carcinoma |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| EP3512839A4 (en) * | 2016-09-18 | 2020-03-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | AGAINST INTERACTION OF YAP1 WITH YCT1 INHIBITORS |
| WO2019090269A1 (en) * | 2017-11-06 | 2019-05-09 | Peng Wang | Processes to produce acalabrutinib |
| US11040945B2 (en) * | 2017-12-06 | 2021-06-22 | Lin Bioscience Pty Ltd. | Tubulin inhibitors |
| EA202092174A1 (en) | 2018-03-14 | 2021-01-15 | Х. Ли Моффитт Кэнсер Сентер Энд Рисерч Инститьют, Инк. | YAP1 INHIBITORS TARGETING THE INTERACTION OF YAP1 WITH OCT4 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4323574B2 (en) * | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | Antitumor agent |
| US5994367A (en) * | 1997-03-07 | 1999-11-30 | The University Of North Carolina At Chapel Hill | Method for treating tumors using 2-aryl-naphthyridin-4-ones |
| JP3739916B2 (en) * | 1997-12-02 | 2006-01-25 | 第一製薬株式会社 | Cytokine production inhibitor |
| ES2247325T3 (en) * | 2001-05-24 | 2006-03-01 | MERCK FROSST CANADA & CO. | INHIBITORS OF 1-BIARIL-1,8-NAFTIRIDIN-4-ONA PHOSPHODIESTERASE-4. |
| JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyne-aryl phosphodiesterase-4 inhibitors |
| MXPA05004754A (en) * | 2002-11-13 | 2005-08-02 | Chiron Corp | Methods of treating cancer and related methods. |
| EP1664030A1 (en) | 2003-09-16 | 2006-06-07 | AstraZeneca AB | Quinazoline derivatives |
| GB0321621D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005091857A2 (en) * | 2004-03-12 | 2005-10-06 | Bayer Pharmaceuticals Corporation | 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders |
| WO2007113548A1 (en) * | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives |
| WO2007113565A1 (en) * | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives as anti-cancer agents |
| US7977338B2 (en) * | 2006-10-16 | 2011-07-12 | Novartis Ag | Phenylacetamides being FLT3 inhibitors |
| US20100144751A1 (en) * | 2007-03-28 | 2010-06-10 | Array Biopharma Inc. | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| FR2917412B1 (en) | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | 7-ALKYNYL, 1,8-NAPHTHYRIDONES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| FR2917413B1 (en) | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | 7-ALKYNYL-1,8-NAPHTHYRIDONES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| FR2933700B1 (en) * | 2008-07-08 | 2010-07-30 | Sanofi Aventis | PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| FR2954943B1 (en) | 2010-01-07 | 2013-03-01 | Sanofi Aventis | ARYLSULFONAMIDE PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
| EP2524915A1 (en) * | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
-
2009
- 2009-11-23 FR FR0905602A patent/FR2952934B1/en not_active Expired - Fee Related
-
2010
- 2010-11-19 AR ARP100104280A patent/AR079077A1/en unknown
- 2010-11-22 MX MX2012005988A patent/MX2012005988A/en active IP Right Grant
- 2010-11-22 KR KR1020127016232A patent/KR20120099732A/en not_active Withdrawn
- 2010-11-22 EA EA201290383A patent/EA201290383A1/en unknown
- 2010-11-22 PE PE2012000710A patent/PE20121338A1/en not_active Application Discontinuation
- 2010-11-22 NZ NZ600108A patent/NZ600108A/en not_active IP Right Cessation
- 2010-11-22 CA CA2781935A patent/CA2781935A1/en not_active Abandoned
- 2010-11-22 TW TW099140242A patent/TWI476197B/en not_active IP Right Cessation
- 2010-11-22 EP EP10799090.5A patent/EP2504338B1/en not_active Not-in-force
- 2010-11-22 CN CN2010800621312A patent/CN102762558A/en active Pending
- 2010-11-22 JP JP2012539393A patent/JP2013511501A/en active Pending
- 2010-11-22 AU AU2010320692A patent/AU2010320692A1/en not_active Abandoned
- 2010-11-22 PH PH1/2012/501004A patent/PH12012501004A1/en unknown
- 2010-11-22 WO PCT/FR2010/052480 patent/WO2011061458A1/en not_active Ceased
- 2010-11-22 BR BR112012012403A patent/BR112012012403A2/en not_active IP Right Cessation
- 2010-11-23 UY UY0001033049A patent/UY33049A/en not_active Application Discontinuation
-
2012
- 2012-05-15 DO DO2012000136A patent/DOP2012000136A/en unknown
- 2012-05-17 TN TNP2012000229A patent/TN2012000229A1/en unknown
- 2012-05-18 GT GT201200154A patent/GT201200154A/en unknown
- 2012-05-20 IL IL219888A patent/IL219888A0/en unknown
- 2012-05-21 EC ECSP12011916 patent/ECSP12011916A/en unknown
- 2012-05-21 CR CR20120261A patent/CR20120261A/en unknown
- 2012-05-22 NI NI201200095A patent/NI201200095A/en unknown
- 2012-05-22 US US13/477,778 patent/US8623893B2/en not_active Expired - Fee Related
- 2012-05-23 CL CL2012001322A patent/CL2012001322A1/en unknown
- 2012-05-23 CO CO12084563A patent/CO6481011A2/en not_active Application Discontinuation
- 2012-06-14 MA MA34962A patent/MA33819B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2504338A1 (en) | 2012-10-03 |
| US20130005724A1 (en) | 2013-01-03 |
| UY33049A (en) | 2011-06-30 |
| DOP2012000136A (en) | 2012-08-15 |
| CO6481011A2 (en) | 2012-07-16 |
| CL2012001322A1 (en) | 2012-08-17 |
| AR079077A1 (en) | 2011-12-21 |
| MA33819B1 (en) | 2012-12-03 |
| FR2952934B1 (en) | 2012-06-22 |
| FR2952934A1 (en) | 2011-05-27 |
| JP2013511501A (en) | 2013-04-04 |
| TW201121971A (en) | 2011-07-01 |
| PH12012501004A1 (en) | 2013-01-14 |
| KR20120099732A (en) | 2012-09-11 |
| WO2011061458A1 (en) | 2011-05-26 |
| MX2012005988A (en) | 2012-09-07 |
| EA201290383A1 (en) | 2013-01-30 |
| NI201200095A (en) | 2012-08-20 |
| IL219888A0 (en) | 2012-07-31 |
| EP2504338B1 (en) | 2015-03-18 |
| GT201200154A (en) | 2013-11-07 |
| NZ600108A (en) | 2013-06-28 |
| US8623893B2 (en) | 2014-01-07 |
| CN102762558A (en) | 2012-10-31 |
| TN2012000229A1 (en) | 2013-12-12 |
| PE20121338A1 (en) | 2012-10-15 |
| BR112012012403A2 (en) | 2017-10-10 |
| CA2781935A1 (en) | 2011-05-26 |
| CR20120261A (en) | 2012-07-04 |
| TWI476197B (en) | 2015-03-11 |
| AU2010320692A1 (en) | 2012-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12011916A (en) | DERIVATIVES OF PIRIDINO-PIRIDINONAS, | |
| ECSP13012363A (en) | DERIVATIVES OF IMIDAZOPIRIDINE, ITS PREPARATION PROCEDURE AND ITS APPLICATION IN THERAPEUTICS | |
| NI201200191A (en) | INDOLIZINE DERIVATIVES, ITS PREPARATION PROCEDURE AND ITS APPLICATION IN THERAPEUTICS | |
| AR088226A1 (en) | HETEROCICLIC PIPERIDINIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| BR112014006660A2 (en) | new bicyclic dihydroquinoline-2-one derivatives | |
| AR089774A1 (en) | DERIVATIVES OF INDOLIZINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR087328A1 (en) | IMIDAZO DERIVATIVES [1,2-B] PIRIDAZINE AND IMIDAZO [4,5-B] PIRIDINA AS JAK INHIBITORS | |
| ECSP099216A (en) | NEW DERIVATIVES OF DIOSMETINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| UY32801A (en) | NEW DIHYDROINDOLONE DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| CO6150147A2 (en) | DERIVED FROM 5,6-BISARIL-2-PIRIDIN-CARBOXAMIDA ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS AS ANTAGONISTS OF UROTENSIN II RECEPTORS | |
| ECSP088677A (en) | PIPERAZINAS AND PIPERIDINAS AS POTENCIADORES 157 OF THE MGLUR5 | |
| CO6551705A2 (en) | DERIVATIVES OF 3.4.4A.10B- TETRAHIDRO-1H-TIOPIRANO- [4.3-C] - ISOQUINOLINA | |
| CO6150150A2 (en) | DERIVATIVES OF 7-ALQUINIL-1,8-NAFTIRIDONAS ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| CO6480974A2 (en) | NEW DERIVATIVES OF (6-OXO-1,6-DIHIDRO-PIRIMIDIN-2-IL) -AMIDA, ITS PREPARATION AND ITS PHARMACEUTICAL USE AS AKT PHOSPHORILATION INHIBITORS (PKB) | |
| SV2009003348A (en) | NEW TRICYCLE DERIVATIVES, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
| AR096040A1 (en) | SUBSTITUTED AND CONDENSED PIRIMIDINE COMPOUNDS AS PDE4B INHIBITORS | |
| AR053340A1 (en) | DERIVATIVES OF TRIFLUORMETILBENZAMIDA AND ITS THERAPEUTIC USES | |
| NI201000215A (en) | NEW DERIVATIVES OF (PIPERAZINYL WITH BRIDGE LINKS) - 1 - ALCANONE AND ITS USE AS INHIBITORS OF p75. | |
| UY37968A (en) | DERIVATIVES OF TETRAZOLILPROPILO AND ITS USE AS FUNGICIDES | |
| UY32575A (en) | DERIVATIVES OF 1H-PIRAZOLO [4,3-C] ISOQUINOLEÍNAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| ECSP12011971A (en) | NEW DERIVATIVES (HETEROCICLO-TETRAHIDRO-PIRIDIN) - (PIPERAZINIL) -1-ALCANONA AND (HETEROCICLO-DIHIDRO-PIRROLIDIN) - (PIPERAZINIL) -1-ALCANONA AND ITS USE AS INHIBITORS OF p75 | |
| UY32768A (en) | NEW CHROME DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| CU20130037A7 (en) | NEW DIHYDROBENZOXATIAZEPIN DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| UY29658A1 (en) | DERIVATIVES OF N - ((4,5-Diphenylpyrimidin-2-IL) METHYL) AMINA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| CU23563A3 (en) | DERIVATIVES OF (TIO) CARBAMOIL-CICLOHEXANO AS ANTAGONISTS OF THE RECEIVER D3 / D2 |